Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (NCT06500273)
A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide. Prior to August 2025, participants may also have received an anti-CD52 monoclonal antibody, ALLO-647, as part of their lymphodepletion regimen.
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (82 Sites)
Showing the first 25 of 82 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Genesis Cancer and Blood Institute — Hot Springs, Arkansas
- Alta Bates Summit Medical Center — Berkeley, California
- City of Hope — Duarte, California
- Cedars-Sinai Medical Center — Los Angeles, California
- University of California, Los Angeles — Los Angeles, California
- University of California, Davis Comprehensive Cancer Center — Sacramento, California
- University of California, San Diego — San Diego, California
- University of California, San Francisco — San Francisco, California
- Rocky Mountain Cancer Centers — Denver, Colorado
- Medical Oncology Hematology Consultants — Newark, Delaware
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
- Advent Health Cancer Institute — Orlando, Florida
- Orlando Health Cancer Institute — Orlando, Florida
- Moffitt Cancer Center — Tampa, Florida
- Augusta University Georgia Cancer Center — Augusta, Georgia
- Northwestern University - Feinberg School of Medicine — Chicago, Illinois
- Rush University Medical Center — Chicago, Illinois
- Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
- IU Simon Comprehensive Cancer Center — Indianapolis, Indiana
- Indiana Blood and Marrow Transplantation — Indianapolis, Indiana
- The University of Kansas Hospital — Kansas City, Kansas
- University of Kentucky Medical Center — Lexington, Kentucky
- University of Louisville Health Brown Cancer Center — Louisville, Kentucky
📞 Contact the Study Coordinator
Phone: (415) 604-5696
Email: clinicaltrials@allogene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Large B-cell Lymphoma
- An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma — Anchorage, Alaska
- Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma — Mobile, Alabama
- Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma — St Louis, Missouri
- Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas — Cleveland, Ohio
- Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Houston, Texas
- CAR-T Followed by Bispecific Antibodies — Omaha, Nebraska
Explore by condition: All Large B-cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.